Introduction Asthma is a chronic and hetero geneous inflammatory disorder of the airways defined by its clinical, physio logical, and patho logical characteristics.
1 It is widely recognized that several different phenotypes 2 characterized both by clinical and physio logical variables and bio markers are grouped together based on a rec ognition of typical symptoms (airflow obstruction and airways hyperresponsiveness), and altogether form an umbrellalike definition of asthma. This heterogeneity is mirrored in the quite complex and descriptive definition of the disease and has a clear impact on our everyday clinical practice. In some difficulttotreat, severe cases extensive diagnostic procedures, differential diagnosis, ed ucation and treatment on a personalized medi cine level are necessary to obtain a clinical suc cess and good control of the disease.
As clearly stated in the inter national guidelines on asthma diagnosis and management -Global Initiative for Asthma (GINA) 1 -there is good ev idence that the clinical manifestations of asthma, including day and night symptoms, sleep distur bances, limitation of activity, impairment of lung function, and use of rescue medication, in most cases may be well controlled with appropriate treatment. Good control of the disease is the main goal of asthma management as it clearly improves patients' quality of life, reduces number of exac erbations, and decreases the cost of health care. Medications used to treat asthma are classified as controllers and relievers.
1 Relievers are lim ited mainly to rapidacting inhaled β 2 agonists (shortacting β 2 agonists -SABAs), which act quickly to reverse bronchoconstriction and relieve symptoms. Controllers should be taken prophy lactically and on a longterm basis to keep asthma in good control, which is believed mainly to be due to their antiinflammatory effects. They include inhaled (ICS) and systemic glucocorticosteroids,
AbsTRACT
Asthma is a chronic and heterogeneous inflammatory disorder of the airways defined by its clinical, physiological and pathological characteristics. Accordingly to currently available guidelines inhaled glucocorticosteroids (ICS) represent the most effective anti-inflammatory medication for the treatment of persistent asthma, and this class of drugs is recommended as the first-line controller therapy both in children and adults. Leukotriene modifiers (LTRAs) are usually used as a second line of add-on therapy, although they may be regarded as the first-line therapy in exercise induced bronchoconstriction, in patients with comorbid allergic rhinitis and in children with asthma and frequent viral infections. A recently published pragmatic (real-life) study showed that LTRAs provide an alternative treatment for asthma, which, at least for the evaluated endpoints, may be as effective as ICS in our every-day practice. To assess how the recent data may affect our every-day practice and current guidelines for clinical management of asthma, it needs to be clearly understood what pragmatic trials add to our knowledge. In our opinion, it is premature to change current guidelines. However, pragmatic and observational studies are clearly needed as they provide additional information to randomized controlled trials. The main goal of all those efforts is to improve asthma control and decrease the burden of the disease for patients and societies. It may be that the future approach will introduce several new strategies based on system biology studies for the treatment of asthma guided in a personalized medicine approach.
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asthma management, asthma treatment, glucocorticosteroids, leukotriene modifiers, pragmatic trials and the main study outcome was asthmarelat ed quality of life. Authors concluded that at 2 months LTRAs were equivalent to ICS both as a firstline controller therapy and as addon to ICS compared with LABAs. At 2 years, the re sults were very similar although not meeting pre defined criteria for equivalence. For another study outcome, improvement of lung function, there were equal improvements over the whole 2year period between the compared treatment strate gies whether LTRAs were given as firstline thera py or as addition to ICSs. This study has initiated much discussion as the results clearly question the current recommendations of asthma treat ment.
1 To provide perspective, studies published to date have certainly documented that LTRAs have antiasthmatic effects, which are undoubt edly better than those of placebo. However, most studies involving comparisons with other treat ments have also suggested that LTRAs are less efficacious than ICS, although a few have been reporting similar asthma control with both ap proaches. 4 In order to conclude how the recent data may affect our everyday practice and cur rent guidelines for clinical management of asth ma, it needs to be clearly understood what prag matic trials add to our knowledge.
Pragmatic and explanatory trials Differences be tween explanatory (mechanistic) and reallife (pragmatic) trials have recently been compre hensively reviewed by Sackett 5 and Ware et al. 6 Briefly, the two approaches differ with respect to the several main elements of a clinical treatment trial, namely, participant eligibility, administra tion of the therapeutic inter vention, and com pliance with study drug use, as well as adherence to protocols, followup intensity and outcome. The main goal of explanatory, RCTs is to evalu ate the efficacy of specific inter vention (a med ication or other medical procedures) in a highly selected cohort of patients, under ideal circum stances, whereas pragmatic trials analyze poten tial role of studied inter vention in a reallife con dition, in a typical group of patients we meet in our everyday practice, suffering from other co morbidities, taking also other drugs, and allow ing for natural variability in adherence to use of prescribed drugs. It is necessary to understand that both approaches are valid and add to our knowledge of the field; however, they address dif ferent clinical and scientific problems. Explana tory trials are designed to evaluate the efficacy of a studied drug in a mechanistic way, by an swering the question "Does this medication work by affecting a particular mechanisms in the dis ease?" Pragmatic trials analyze the effectiveness of a drug which already is known to work un der ideal conditions. The primary question here is whether this medication is efficacious in typi cal patients, in everyday settings, where sever al factors can influence the outcome of an inter vention (TAbLE) . Results of such a study are of par ticular value for health care providers. Combined leukotriene modifiers, longacting β 2 agonists (LABAs, to be used only in combination with ICS), theophylline, and antiimmunoglobulin E.
The main strategy for asthma therapy may be summarized as a stepup/stepdown approach. In those patients in whom asthma is not well con trolled (as defined by frequency of symptoms, limitation of activities, need for rescue medica tions, lung functions, and exacerbations), an in crease in dose of the currently used controller or adding another drug is the recommended ac tion. On the other hand, in patients where asth ma is well controlled, the dose or the number of controllers should be reduced to limit the possi bility of side effects and decrease the costs. Ac cording to the GINA guidelines, 1 ICS represent the most effective antiinflammatory medication for the treatment of persistent asthma, and this class of drugs is recommended as the firstline controller therapy both in children and adults. Leukotriene modifiers are usually used as a sec ond line of addon therapy, although they may be regarded as the firstline therapy in exercise induced bronchoconstriction, in patients with comorbid allergic rhinitis, and in children with asthma and frequent viral infections.
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In current guidelines, recommendations re garding the choice of medications, prevention, and strategies for management are based al most exclusively on the results of doubleblind, randomized controlled trials (RCTs). RCTs pro vide a good insight into mechanism of drug ac tion, efficacy, and acute side effects. On the oth er hand, as a consequence of their strict scientif ic design, there are also some significant limita tions of RCTs. The main issue is usually artificial selection of the study group. Strict inclusion cri teria which guarantee that the patients' group is homo genous and the diagnosis of the studied disease is clear, at the same time lead to preselec tion of a cohort that does not mirror the reallife conditions which we face in our clinical practice. In addition, due to high costs, RCTs are usually relatively shortterm studies, rarely exceeding 1 year of followup, and thus may be less powerful for evaluation of longterm factors such as vari ability of the disease, exacerbationrate, com pliance, tolerability, longterm adverse events, and patients' preferences. Other options to in vestigate the effects of treatment include obser vational (prospective and retrospective) stud ies and pragmatic trials. The main advantage of such reallife studies is that the study groups and therapeutic conditions are reasonably similar to those seen in everyday practice.
One recently published reallife pragmatic study was the paper by Price D et al. 4 The main goal of that trial was to evaluate realworld ef fectiveness of leukotrienereceptor antagonist (LTRA) as compared with either ICS as a firstline asthma controller, or LABAs as addon thera py in patients already receiving ICS. More than 650 patients were included and followed up for up to 2 years by their primary care physicians However, from the method section and the re sults of the trial, it is clear that several factors could have significant impact on the outcome. The inter vention here was flexible, with signif icant crossover between treatment groups, pos sible use of concomitant therapies, possible en rolment of misdiagnosed patients, and possi ble spontaneous improvements. But attempt ing to assess the influence of different factors for the study outcome, we would suggest that the way of administration of the study drugs (tab lets vs. inhalers) may have been the most impor tant factor for the overall study outcome. Accord ingly, adherence to LTRAs was significantly better than it was to the other drugs in the study (65% vs. 41% for ICS) and (74% vs. 46% for the LABA arm). It is well known that compliance with tab lets (especially those taken once daily) is much better than with inhaled drugs. 7
Conclusions
The reallife study by Price et al. 4 showed that LTRAs provide an alternative treat ment for asthma, which, at least for the evaluat ed endpoints, may be as effective as ICS in our everyday practice. Antileukotrienes may have several advantages in clinical practice. First, mon telukast and zafirlukastare are available as gener ic medications in most countries, thus the cost of such treatment is decreasing. Second, many pa tients with asthma have rhinitis, and LTRAs may contribute to the treatment of rhinitis symptoms as well. Third, antileukotrienes have a very good safety profile. This may be contrasted to corti costeroids, where the common "steroid phobia" in many patients, as in fact suggested by the tri al of Price et al., 4 in addition may have a signifi cant impact on adherence to therapy. On the oth er hand, ICS act broadly on several targets in the pathophysio logical mechanisms of chron ic inflammation, whereas LTRAs block only one pathway. Another therapeutic approach may be combining antileukotrienes with antihistamines, which has been proved to yield additional pro tection in allergenchallenge studies in atopic asthma.
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It needs to be made clear that the trial of Price et al. 4 has not proved that LTRAs are equal anti inflammatory drugs to ICS, only that when used in the nonsupervised environment, in the prima ry care setting, there seems to be no major differ ence in overall treatment response. As mentioned above, the most plausible factor behind these somewhat surprising study results may be that the oral administration has advantages over in haled medications more than pharmaco logic dif ferences between the two classes of drugs.
There are no doubts that the paper by Price et al. 4 has started an inter esting discussion that may lead to an increase in our understanding of the clinical needs in asthma treatment. It is premature to change current guidelines but pragmatic and observational studies are clearly needed as they provide additional information to RCTs. The main goal of all those efforts is to with pharmacoeconomy studies, pragmatic tri als may help address the question of which med ication is the most costeffective in reallife con ditions, and thus help create a health care poli cy. 5, 6 There is no doubt that pragmatic trials give several inter esting additional pieces of informa tion. When results of RCTs are analysed, a mes sage that a particular medication is more active than placebo is usually available. However, one can ask how does it add to our clinical practice as we do not treat our patients with placebos? This issue has been addressed by some regula tors, and nowadays the approval of new medi cines often requires proven effectiveness over and above the current "gold standard" treatment, or at least noninferiority. As stated by Ware et al. 6 "… pragmatic trials are designed to study realworld practice and represent less 'perfect' experimen tal design than efficacy trials". The challenge for health care providers and individual physicians is to assess how to integrate the information from these two types of studies, which in essence cap ture very different dimension of the evaluation of management strategies.
Impact of pragmatic trials on clinical practice in asthma Some of the main weaknesses of the pragmatic trial strategy is thus the flexible study design, the uncertain compliance with treat ment, and the losses of patients during followup. It is, therefore, difficult to identify which fac tor contributed most to the overall study result. The pragmatic study of Price et al. 4 is a good ex ample of these inconsistencies. The main mes sage of their study is that there is little, if any, dif ference between LTRAs and ICS in maintaining asthma control as firstline or addon treatments. improve asthma control and decrease the burden of the disease for patients and societies. It may be that the future will introduce several new and personalized strategies for the treatment of asth ma guided by patient specific patterns of changes in lung function 10 or bio markers. 11 For example, new antagonists of prostaglandins or key cytok ines present promising effects in animal and clini cal models. 12 It is highly probable that future gen eration of therapies for asthma will combine sev eral selective molecules, preferably given orally as a oncedaily tablet, to block main proinflamma tory pathways and significantly improve disease control. This scenario is similar to current medi cal practice in hypertension where the combina tion of several drugs gives a possibility to design a patientoriented (depending on comorbidities, preferences, tolerance, etc.) effective therapeu tic approach.
